1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Alberto Abaterusso
Alberto Abaterusso
Articles (709) 

Janssen, AbbVie's Imbruvica Achieves PFS in Innovate Study

The primary endpoints was achieved on patients affected with Waldenström's macroglobulinemia at the end of the Phase 3 of the clinical trial

December 06, 2017 | About:

The progression-free survival (or PFS) primary endpoint was successfully met by researchers of Janssen – a unit of Johnson & Johnson's (NYSE:JNJ) Pharmaceutical Research and Development – at the end of Phase 3 of a clinical trial, called Innovate, Janssen reported yesterday Dec. 5.

During the study, Imbruvica (ibrutinib) was evaluated by Janssen on patients affected with relapsed/refractory Waldenström's macroglobulinemia, which is a rare form of non-Hodgkin lymphoma.

Imbruvica, which is developed and commercialized by Janssen Biotech Inc., together with AbbVie’s (NYSE:ABBV) Pharmacyclics LLC, was evaluated on patients in a combined therapy with Rituxan. The latter is the brand name under which Roche Group’s (RHHBY) Genentech and Biogen Inc. (NASDAQ:BIIB), jointly marketed rituximab, a medication used for the treatment of certain types of cancer and autoimmune diseases.

The patients who were enrolled in the study had never undergone any kind of treatment for Waldenström's macroglobulinemia.

Janssen is working with AbbVie’s Pharmacyclics to globally share the results of the trial with health authorities.

In January 2015, Imbruvica was approved by the Food and Drug Administration for its commercialization in the U.S. as a treatment for patients with Waldenström's macroglobulinemia.

Waldenström's macroglobulinemia is a cancer cells and non-Hodgkin lymphoma’s (NHL) type, which produces abnormal levels of a certain type of antibody (immunoglobulin M, or IgM) – a protein that is known as macroglobulin – leading to several problems of excess bleeding, vision problems, plus problems to the nervous system.

This form of non-Hodgkin lymphoma also leads to problems of anaemia or a low count of red blood cells and to problems for the organism to successfully fight infections because the cancer causes a drop in the blood of white cells.

Imbruvica is a drug that inhibits Bruton's tyrosine kinase, a protein that plays a key role in the maturation of B-Cells. Since specific cancer cells such as WM cells use this protein to metastasise, its inhibition prevents them to persist and disseminate in the body.

The company says that “Worldwide, IMBRUVICA was used to treat more than 90,000 patients to date”.

Johnson & Johnson is trading at $139.67 per share on the New York Stock Exchange, with a market capitalization of $ 375.23 billion, a price to book (P/B) ratio of 5.09 versus an industry median of 2.86, a price to earnings (P/E) ratio of 24.24 versus an industry median of 25.41 and a price to sales (P/S) ratio of 5.18 versus an industry median of 2.79.

AbbVie Inc. is trading at $95.41 per share on the New York Stock Exchange, with a market capitalization of $152.32 billion, a price to book (P/B) ratio of 22.75 versus an industry median of 2.86, a price to earnings (P/E) ratio of 23.22 versus an industry median of 25.41 and a price to sales (P/S) ratio of 5.63 versus an industry median of 2.79.

Disclosure: no positions in any stock mentioned in this article.

About the author:

Alberto Abaterusso
Alberto Abaterusso is a freelance writer based in The Netherlands. He primarily writes about gold, silver and precious metals mining stocks. His articles have also been widely linked by popular sites, including MarketWatch, Financial Times, 24hGold, Investopedia, Financial.org, CNBS, MSN Money, Zachs, Reuters and others. Alberto holds a MBA from Università degli Studi di Bari (Italy), Aldo Moro.

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by Alberto Abaterusso


User Generated Screeners


Thomas W. Eaton, Sr.Lynch - Stalwart
rael2222T
pbarker46Dividend candidates
richsmithRS Value 12/15
CarstinSingapore EV/EBIT 5.0 and belo
jmeekinsCheap Tax Reform
daftheaderNcav div
daftheaderNet net div
srichardsonGROWTH ROC FCF YIELD
rori77Roberto
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK